Phase 3 Results: Imsidolimab Provides Positive Outlook in Generalized Pustular Psoriasis (GPP)
source: shutterstock.com

Phase 3 Results: Imsidolimab Provides Positive Outlook in Generalized Pustular Psoriasis (GPP)

Just about one month ago, clinical-stage biotechnology company AnaptysBio announced the availability of positive top-line results from two Phase 3 clinical studies: GEMINI-1 and GEMINI-2. Both studies sought to assess…

Continue Reading Phase 3 Results: Imsidolimab Provides Positive Outlook in Generalized Pustular Psoriasis (GPP)